Amir Nashat is a Managing Partner in Polaris’ Boston office. He joined Polaris in 2002 and focuses on investments in healthcare.
Amir currently represents Polaris as a Director of AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences (NASDAQ: SELB), Sofregen Medical, and Syros Pharmaceuticals (NASDAQ: SYRS) Additionally, Amir has served as a Director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene), and Sun Catalytix (Lockheed Martin). At Living Proof and Sun Catalytix, Amir served as the company’s initial CEO and currently serves as acting CEO of Olivo Labs.
Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT. He previously served on the Board of the New England Venture Capital Association. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”
Prior to joining Polaris, Amir completed his PhD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.